Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study
Hamza Khan, Muhammad Saqib Khan, Sheraz Khan, Fang Liu, Quan Feng, Irfan Ahmad, Ge Tan · 2026
Read Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study by Hamza Khan, Muhammad Saqib Khan, Sheraz Khan, Fang Liu, Quan Feng, Irfan Ahmad, Ge Tan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13275357.txt.
Description
Hamza Khan and co-authors reviewed real world use of rimegepant to prevent migraine in a 2026 retrospective cohort study. Rimegepant is a pill that blocks a migraine related receptor and is approved for both attacks and prevention, but everyday evidence was thin. Their hospital in Chongqing examined three months of treatment.
Records covered forty adults, most of them women, split almost evenly between chronic and episodic migraine, all taking the drug every other day. Monthly migraine days collapsed from an average above seventeen to under three, and headache days fell sharply as well. Disability and impact scores improved markedly, and quality of life rose. Gains came mostly in the first month, and by month three the two migraine types looked alike despite different starting points.
Catalog record
| CREATOR | Hamza Khan, Muhammad Saqib Khan, Sheraz Khan, Fang Liu, Quan Feng, Irfan Ahmad, Ge Tan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |